ACAD Acadia Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ACAD

Price (delayed)

$16.82

Market cap

$2.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$2.62B

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who ...

Highlights
The EPS has soared by 72% YoY and by 60% QoQ
The net income has surged by 72% year-on-year and by 59% since the previous quarter
The quick ratio has declined by 44% year-on-year
The gross margin has declined by 3.8% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.acadia-pharm.com
Peers: VNDA PFE JNJ BMY

Key stats

What are the main financial stats of ACAD
Market
Shares outstanding
164.77M
Market cap
$2.77B
Enterprise value
$2.62B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.4
Price to sales (P/S)
3.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
Earnings
Revenue
$726.44M
EBIT
-$51.04M
EBITDA
-$45.48M
Free cash flow
$16.65M
Per share
EPS
-$0.37
Free cash flow per share
$0.1
Book value per share
$2.63
Revenue per share
$4.43
TBVPS
$4.17
Balance sheet
Total assets
$748.96M
Total liabilities
$317.2M
Debt
$47.8M
Equity
$431.76M
Working capital
$361.87M
Liquidity
Debt to equity
0.11
Current ratio
2.42
Quick ratio
2.15
Net debt/EBITDA
3.22
Margins
EBITDA margin
-6.3%
Gross margin
94.3%
Net margin
-8.4%
Operating margin
-10.1%
Efficiency
Return on assets
-9.1%
Return on equity
-15.7%
Return on invested capital
-20%
Return on capital employed
-10.3%
Return on sales
-7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ACAD stock price

How has the Acadia Pharmaceuticals stock price performed over time
Intraday
-1.46%
1 week
-1.87%
1 month
-10.05%
1 year
-15.98%
YTD
-46.28%
QTD
-9.03%

Financial performance

How have Acadia Pharmaceuticals's revenue and profit performed over time
Revenue
$726.44M
Gross profit
$684.8M
Operating income
-$73.38M
Net income
-$61.29M
Gross margin
94.3%
Net margin
-8.4%
The net margin has soared by 80% YoY and by 64% QoQ
The operating margin has soared by 77% YoY and by 59% QoQ
The net income has surged by 72% year-on-year and by 59% since the previous quarter
The operating income has soared by 67% YoY and by 52% from the previous quarter

Growth

What is Acadia Pharmaceuticals's growth rate over time

Valuation

What is Acadia Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.4
P/S
3.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.61
The EPS has soared by 72% YoY and by 60% QoQ
ACAD's price to book (P/B) is 35% lower than its last 4 quarters average of 9.8 and 26% lower than its 5-year quarterly average of 8.6
The company's equity rose by 19% QoQ and by 8% YoY
ACAD's P/S is 64% below its 5-year quarterly average of 10.6 and 41% below its last 4 quarters average of 6.4
ACAD's revenue is up by 40% YoY and by 15% QoQ

Efficiency

How efficient is Acadia Pharmaceuticals business performance
The ROS has soared by 83% YoY and by 66% QoQ
Acadia Pharmaceuticals's return on assets has surged by 74% YoY and by 61% QoQ
The ROE has soared by 69% YoY and by 60% from the previous quarter
ACAD's return on invested capital has surged by 64% year-on-year and by 57% since the previous quarter

Dividends

What is ACAD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ACAD.

Financial health

How did Acadia Pharmaceuticals financials performed over time
The total assets is 136% more than the total liabilities
The total liabilities has soared by 69% YoY and by 17% QoQ
The quick ratio has declined by 44% year-on-year
The debt is 89% lower than the equity
The company's equity rose by 19% QoQ and by 8% YoY
The debt to equity has declined by 15% since the previous quarter and by 15% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.